Physician profile
Chase D Bailey
NPI 1790047157
$2,274.96
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $738 · 2022: $656 · 2023: $745 · 2024: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.04 | 2021-2024 | |
| Lilly USA, LLC | $303.24 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $184.67 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $136.89 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $133.31 | 2021-2023 | Flumist Quadrivalent |
| Biohaven Pharmaceutical Holding Company LTD. | $130.65 | 2022 | |
| Pfizer INC. | $101.10 | 2021-2023 | |
| Amarin Pharma, INC. | $71.51 | 2021 | |
| Novo Nordisk INC | $55.87 | 2021-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $55.66 | 2021-2023 | |
| Astellas Pharma US INC | $54.18 | 2021-2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.55 | 2021 | |
| Lucid Diagnostics INC. | $46.71 | 2022 | |
| Amgen INC. | $44.14 | 2021-2022 | |
| Dynavax Technologies Corporation | $44.02 | 2022-2023 | Heplisav-B |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $33.21 | 2022-2023 | |
| Sanofi Pasteur INC. | $20.58 | 2023 | |
| Lundbeck LLC | $20.19 | 2023 | Vyepti |
| Ultragenyx Pharmaceutical INC. | $20.14 | 2022 | |
| Baxter Healthcare | $18.44 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Biohaven Pharmaceuticals, INC. | $17.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.27 | 2021 | |
| Modernatx, INC. | $16.22 | 2023 | Moderna Covid-19 Vaccine |
| Takeda Pharmaceuticals U.S.A., INC. | $15.54 | 2021 | |
| Genentech USA, INC. | $13.99 | 2021 | |
| Organon LLC | $12.13 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.